Stella Manta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stella Manta has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alexandros Komiotis
Department of Pharmacy, Frederick University, Nicosia 1036, Cyprus
1 shared publication - Apostolia Gkoutzivelaki
Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
1 shared publication - Athanasios Papakyriakou
Institute of Biosciences & Applications, National Centre for Scientific Research “Demokritos”, Ag. Paraskevi, 15341 Athens, Greece
1 shared publication - Barry James Campbell
Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 3GE, UK
1 shared publication - Charalampos Triantis
Department of Pharmacy, Frederick University, Nicosia 1036, Cyprus
1 shared publication - Chrysoula Mikra
Laboratory of Organic Chemistry, Faculty of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6431
Novel 3-Amino-2-methylquinazolinone NF-κB Inhibitors: Synthesis and Potential Anti-Inflammatory Function
The canonical NF-κB pathway is a major regulator of inflammatory responses, and its persistent activation has been linked to chronic inflammatory diseases and cancer development. It is therefore important to develop effective NF-κB inhibitors that can potentially be utilized in further preclinical studies. In this study, we have synthesized various quinazolinone compounds using novel methodologies. We specifically utilized a two-step protocol comparing an established protocol to a modified alternative procedure and then successfully established a novel one-pot multi-component reaction. All quinazolinones were tested based on their capacity to inhibit tumor necrosis factor-induced NF-κB activation using a commercial transgenic HeLa reporter cell-line. Among the eighteen molecules tested, two compounds affected the NF-κB-dependent luciferase activity, the 5o (3-amino-6-hydroxy-2-methylquinazolin-4(3H)-one) and 10 (N-(6-bromo-2-methyl-4-oxoquinazolin-3(4H)-yl)-4-nitrobenzamide). Only the 5o though, bearing OH at R1 (6 position), attenuated the production of pro-inflammatory interleukin 6 in lipopolysaccharide-stimulated human primary macrophage cultures. Molecular docking analysis provides supportive computational evidence that 5o could interact with the p65/DNA complex and therefore could potentially be developed for further studies that aim to inhibit the canonical NF-κB pathway.
- 20 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6431
Open AccessNovel 3-Amino-2-methylquinazolinone NF-κB Inhibitors: Synthesis and Potential Anti-Inflammatory Function
The canonical NF-κB pathway is a major regulator of inflammatory responses, and its persistent activation has been linked to chronic inflammatory diseases and cancer development. It is therefore important to develop effective NF-κB inhibitors that can potentially be utilized in further preclinical studies. In this study, we have synthesized various quinazolinone compounds using novel methodologies. We specifically utilized a two-step protocol comparing an established protocol to a modified alternative procedure and then successfully established a novel one-pot multi-component reaction. All quinazolinones were tested based on their capacity to inhibit tumor necrosis factor-induced NF-κB activation using a commercial transgenic HeLa reporter cell-line. Among the eighteen molecules tested, two compounds affected the NF-κB-dependent luciferase activity, the 5o (3-amino-6-hydroxy-2-methylquinazolin-4(3H)-one) and 10 (N-(6-bromo-2-methyl-4-oxoquinazolin-3(4H)-yl)-4-nitrobenzamide). Only the 5o though, bearing OH at R1 (6 position), attenuated the production of pro-inflammatory interleukin 6 in lipopolysaccharide-stimulated human primary macrophage cultures. Molecular docking analysis provides supportive computational evidence that 5o could interact with the p65/DNA complex and therefore could potentially be developed for further studies that aim to inhibit the canonical NF-κB pathway.
- Open Access
- 11 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1738
Design, Synthesis, Antiproliferative Potency and In Silico Studies of Novel Alkynyl Quinazolines as Potential EGFR Inhibitors
The epidermal growth factor receptor (EGFR) is a highly attractive and promising target for novel anticancer agents, particularly for non-small-cell lung cancer (NSCLC), due to its crucial role in regulating cell survival and proliferation. Despite the development of first-generation reversible inhibitors like Gefitinib and Erlotinib, acquired resistance necessitated the discovery of highly potent irreversible inhibitors effective against drug-resistant mutants. Molecular docking calculations utilizing both EGFR conformations identified five top-ranked compounds (QN012, QN017, QN019, QN022, and QN023) proposed for synthesis and biological evaluation. These in silico studies predicted high inhibitory activity against the active and inactive state of EGFR. Herein, we report the design, synthesis and biological evaluation of novel 4-anilino quinazoline derivatives, bearing various alkynyl substituents at position 6, expected to bind to the hinge Met793 residue of EGFR. The effects of the derivatives on various cancer cell lines in terms of cytotoxic/cytostatic activity, interference with cell cycle phase distribution, and suppression of EGFR phosphorylation set the basis for the design of more potent derivatives.
- 11 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1738
Open AccessDesign, Synthesis, Antiproliferative Potency and In Silico Studies of Novel Alkynyl Quinazolines as Potential EGFR Inhibitors
The epidermal growth factor receptor (EGFR) is a highly attractive and promising target for novel anticancer agents, particularly for non-small-cell lung cancer (NSCLC), due to its crucial role in regulating cell survival and proliferation. Despite the development of first-generation reversible inhibitors like Gefitinib and Erlotinib, acquired resistance necessitated the discovery of highly potent irreversible inhibitors effective against drug-resistant mutants. Molecular docking calculations utilizing both EGFR conformations identified five top-ranked compounds (QN012, QN017, QN019, QN022, and QN023) proposed for synthesis and biological evaluation. These in silico studies predicted high inhibitory activity against the active and inactive state of EGFR. Herein, we report the design, synthesis and biological evaluation of novel 4-anilino quinazoline derivatives, bearing various alkynyl substituents at position 6, expected to bind to the hinge Met793 residue of EGFR. The effects of the derivatives on various cancer cell lines in terms of cytotoxic/cytostatic activity, interference with cell cycle phase distribution, and suppression of EGFR phosphorylation set the basis for the design of more potent derivatives.
- 30 November 2022
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 42 (5) , 407-425
Unusual seven-membered ring sugars and nucleosides: synthesis and biological properties
Methods of the synthesis and the investigation of the properties of unnatural seven-memebered cyclic sugars and nucleosides, are of high interest. Septanoses provide conformationally more flexible sugars and due to their similarity to natural carbohydrates they have interesting and potentially useful physical, chemical, and biological properties. Additionally, nucleosides with seven-membered sugar moiety are commonly found in natural products and biologically active molecules. Modification of such nucleosides hold great promise as therapeutic agents. The present review describes the chemical synthesis and biological properties of septanoses as well as nucleosides containing septanosyl moieties.
- 30 November 2022
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 42 (5) , 407-425
Unusual seven-membered ring sugars and nucleosides: synthesis and biological properties
Methods of the synthesis and the investigation of the properties of unnatural seven-memebered cyclic sugars and nucleosides, are of high interest. Septanoses provide conformationally more flexible sugars and due to their similarity to natural carbohydrates they have interesting and potentially useful physical, chemical, and biological properties. Additionally, nucleosides with seven-membered sugar moiety are commonly found in natural products and biologically active molecules. Modification of such nucleosides hold great promise as therapeutic agents. The present review describes the chemical synthesis and biological properties of septanoses as well as nucleosides containing septanosyl moieties.
- 1 October 2008
- Published by Bentham Science Publishers Ltd. in Anti-Infective Agents
- Vol. 7 (4) , 219-244
Antiviral Unsaturated Nucleosides
In the search for effective, selective and nontoxic antiviral agents, a variety of nucleoside analogues have been synthesized, with different functionalities in the carbohydrate moiety. Unsaturated nucleoside analogues are recognized as an important class of biologically active compounds and appear to be prominent drugs in the management of several viral infections, including HSV, HIV, HBV, HCV and HCMV infections. Currently, unsaturated nucleoside mimetics, such as stavudine, abacavir and entecavir have been approved for the treatment of viral infections, while elvucitabine and β-L-2β- F-d4C are in clinical trials. The purpose of this review is to give an update of the recent developments on unsaturated nucleoside and nucleoside analogues, in both cyclic and acyclic forms, which possess promising therapeutic potential, mainly antiviral. It covers analogues with ring sizes from three to six and provides useful data, in the aim to enhance chemical reactivity or to study the fixation of the sugar conformation.
- 1 October 2008
- Published by Bentham Science Publishers Ltd. in Anti-Infective Agents
- Vol. 7 (4) , 219-244
Antiviral Unsaturated Nucleosides
In the search for effective, selective and nontoxic antiviral agents, a variety of nucleoside analogues have been synthesized, with different functionalities in the carbohydrate moiety. Unsaturated nucleoside analogues are recognized as an important class of biologically active compounds and appear to be prominent drugs in the management of several viral infections, including HSV, HIV, HBV, HCV and HCMV infections. Currently, unsaturated nucleoside mimetics, such as stavudine, abacavir and entecavir have been approved for the treatment of viral infections, while elvucitabine and β-L-2β- F-d4C are in clinical trials. The purpose of this review is to give an update of the recent developments on unsaturated nucleoside and nucleoside analogues, in both cyclic and acyclic forms, which possess promising therapeutic potential, mainly antiviral. It covers analogues with ring sizes from three to six and provides useful data, in the aim to enhance chemical reactivity or to study the fixation of the sugar conformation.